This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.
Why Jazz Pharmaceuticals (JAZZ) Might Surprise This Earnings Season
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
by Zacks Equity Research
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) third-quarter 2022 earnings beat estimates while revenues miss the same. The company tightens its revenue guidance for 2022. Shares down in after-hours trading.
Can Cigna's (CI) Q3 Earnings Beat on Evernorth Performance?
by Zacks Equity Research
The third-quarter results of Cigna (CI) are likely to reflect a rise in total medical customers.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.
Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.
Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.
Zacks.com featured highlights include Albemarle, Chevron, Jazz Pharmaceuticals and Cummins
by Zacks Equity Research
Albemarle, Chevron, Jazz Pharmaceuticals and Cummins are part of Zacks Screen of the Week article.
4 High Earnings Yield Picks That You Shouldn't Ignore
by Rimmi Singhi
ALB, CVX, JAZZ and CMI are a few high earnings yield value picks with solid upside potential.
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
What's in Store for Gilead (GILD) This Earnings Season?
by Zacks Equity Research
Investors focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports third-quarter 2022 results.
Molina Healthcare (MOH) to Post Q3 Earnings: What to Expect
by Zacks Equity Research
Molina Healthcare's (MOH) Q3 results are expected to reflect better premiums and membership growth in its Medicaid and Medicare businesses, partly offset by steep general and administrative costs.
Wall Street Analysts Predict a 48% Upside in Jazz (JAZZ): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 48.5% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics
by Zacks Equity Research
Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.
Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals
by Zacks Equity Research
Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of the candidate in all territories except Asia-Pacific.
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
5 Stocks to Bet on in an Innovation-Driven Drug Industry
by Kinjel Shah
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
Here's Why You Should Consider Investing in JAZZ Stock Now
by Zacks Equity Research
JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
Is Deciphera Pharmaceuticals (DCPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.